Condition: Hematological Malignancies · Sponsor: Smart Immune SAS
The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients with hematological malignancies.
This description comes directly from the study's public registry record.
Frédéric LEHMANN, MD · +32 (0) 492 46 23 55 · frederic.lehmann@smart-immune.com
Laura SIMONS, MD, PhD · laura.simons@smart-immune.com
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Cancer Center (MSKCC) | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04959903